Pharmacologic treatment of the ovarian endometrioma

References

• Missmer SA, Cramer DW. The epidemiology of endometriosis. Obstet Gynecol Clin North Am. 2003;30:1–19.
   PubMed Web of Science ®Google Scholar
• Viganò P, Parazzini F, Somigliana E, et al. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol. 2004;18:177–200.
   PubMed Web of Science ®Google Scholar
• The Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility. Fertil Steril. 2006;86(Suppl 4):S156–S160.
   PubMedGoogle Scholar
• de Ziegler D, Borghese B, Chapron C. Endometriosis and infertility: pathophysiology and management. Lancet. 2010;376:730–738.
   PubMed Web of Science ®Google Scholar
• Nisolle M, Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril. 1997;68:585–596.
   PubMed Web of Science ®Google Scholar
• Menakaya UA, Adno A, Lanzarone V, et al. Integrating the concept of advanced gynaecological imaging for endometriosis. Aust NZ J Obstet Gynaecol. 2015;55:409–412.
   PubMed Web of Science ®Google Scholar
• Brosens I, Gargett C, Guo S-W, et al. Origins and progression of adolescent endometriosis. Reprod Scie. 2016. Mar 31. Pii: 1933719116637919. [Epub ahead of print]
   PubMedGoogle Scholar
• Burkhardt M, Renner SP. Radikalität der operativen Therapie bei Endometriose: Ist weniger mehr? [Radicality of surgical treatment for endometriosis: is less more?]. Gynakol Endokrinol. 2016;14:15–20.
   Google Scholar
• Guo SW. Emerging drugs for endometriosis. Expert Opin Emerg Drugs. 2008;13:547–571.
   PubMed Web of Science ®Google Scholar
• Benagiano G, Guo SW, Puttemans P, et al. Adolescent endometriosis: progress in diagnosis and management. J Pediatr Adolesc Gynecol. Accepted for publication 2016.
   Web of Science ®Google Scholar
• Psaroudakis D, Hirsch M, Davis C. Review of the management of ovarian endometriosis: paradigm shift towards conservative approaches. Curr Opin Obstet Gynecol. 2014;26:266–274.
   PubMed Web of Science ®Google Scholar
• Benagiano G, Petraglia F, Gordts S, et al. A new approach to the management of the ovarian endometrioma to prevent tissue damage and recurrence. Reprod BioMed Online. 2016. [Epub ahead of print 2016 Mar 11]. DOI:10.1016/j.rbmo.2016.03.001
   PubMed Web of Science ®Google Scholar
• Tafi E, Leone Roberti Maggiore U, Alessandri F, et al. Advances in pharmacotherapy for treating endometriosis. Expert Opin Pharmacother. 2015;16:2465–2483.
   PubMed Web of Science ®Google Scholar
• Guo SW, Ding D, Shen M, et al. Dating endometriotic ovarian cysts based on the content of cyst fluid and its potential clinical implications. Reprod Sci. 2015;22:873–883.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ding D, Liu X, et al. Activated platelets induce estrogen receptor β expression in endometriotic stromal cells. Gynecol Obstet Invest. 2015;80:187–192.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Duan J, Liu X, et al. Platelets drive smooth muscle metaplasia and fibrogenesis in endometriosis through epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation. Mol Cell Endocrinol. 2016;428:1–16.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Duan J, Olson M, et al. Cellular changes consistent with epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the progression of experimental endometriosis in Baboons. Reprod Sci. 2016 Apr 12. pii: 1933719116641763. [Epub ahead of print]
   Google Scholar
• Li J, Dai Y, Zhu H, et al. Endometriotic mesenchymal stem cells significantly promote fibrogenesis in ovarian endometrioma through the Wnt/β-catenin pathway by paracrine production of TGF-β1 and Wnt1. Hum Reprod. 2016;31:1224–1235.
   PubMed Web of Science ®Google Scholar
• Kitajima M, Defrère S, Dolmans M-M, et al. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril. 2011;96:685–691.
   PubMed Web of Science ®Google Scholar
• Kitajima M, Dolmans -M-M, Donnez O, et al. Enhanced follicular recruitment and atresia in cortex derived from ovaries with endometriomas. Fertil Steril. 2014;101:1031–1037.
   PubMed Web of Science ®Google Scholar
• Brosens IA. Endometriosis-a disease because it is characterized by bleeding. Am J Obstet Gynecol. 1997;176:263–267.
   PubMed Web of Science ®Google Scholar
• Guo SW, Ding D, Geng JG, et al. P-selectin as a potential therapeutic target for endometriosis. Fertil Steril. 2015;103:990–1000.e8.
   PubMed Web of Science ®Google Scholar
• Guo S-W, Ding D, Liu X. Anti-platelet therapy is efficacious in treating endometriosis induced in mouse. Reprod BioMed Online. 2016. [Epub ahead of print].
   PubMedGoogle Scholar
• Brosens IA, Puttemans PJ, Deprest J. The endoscopic localization of endometrial implants in the ovarian chocolate cyst. Fertil Steril. 1994;61:1034–1038.
   PubMed Web of Science ®Google Scholar
• Qiu J-J, Liu M-H, Zhang Z-X, et al. Transvaginal color Doppler sonography predicts ovarian interstitial fibrosis and microvascular injury in women with ovarian endometriotic cysts. Acta Obstetr Gynecol Scand. 2012;91:605–612.
   PubMed Web of Science ®Google Scholar
• Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20:2698–2704.
   PubMed Web of Science ®Google Scholar
• Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–412.
   PubMed Web of Science ®Google Scholar
• Hart RJ, Hickey M, Maouris P, et al. Excisional surgery versus ablative surgery for ovarian endometriomata. Cochrane Database Syst Rev. 2008;CD004992.
   Google Scholar
• Carmona F, Martinez-Zamora MA, Rabanal A, et al. Ovarian cystectomy versus laser vaporization in the treatment of ovarian endometriomas: a randomized clinical trial with a five-year follow-up. Fertil Steril. 2011;96:251–254.
   PubMed Web of Science ®Google Scholar
• Guo SW. An overview of the current status of clinical trials on endometriosis: issues and concerns. Fertil Steril. 2014;101:183–190.
   PubMed Web of Science ®Google Scholar
• Kim YA, Kim MR, Lee JH, et al. Gonadotropin-releasing hormone agonist reduces aromatase cytochrome p450 and cyclooxygenase-2 in ovarian endometrioma and eutopic endometrium of patients with endometriosis. Gynecol Obstet Invest. 2009;68:73–81.
   PubMed Web of Science ®Google Scholar
• Khan KN, Kitajima M, Hiraki K, et al. Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma. Hum Reprod. 2010;25:2878–2890.
   PubMed Web of Science ®Google Scholar
• Khan K, Kitajima M, Hiraki K, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod. 2010;25:642–653.
   PubMed Web of Science ®Google Scholar
• Hamid AM, Madkour WA, Moawad A, et al. Does cabergoline help in decreasing endometrioma size compared to LHRH agonist? A prospective randomized study. Arch Gynecol Obstet. 2014;290:677–682.
   PubMed Web of Science ®Google Scholar
• Schweppe K-W. The current place of progestins in the treatment of endometriosis. Expert Rev of Obstet Gynecol. 2012;7:141–148.
   Google Scholar
• Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Intl J Fert Women’s Med. 1998;43:24–27.
   PubMedGoogle Scholar
• Muneyyirci-Delale O, Jalou S. Long-term treatment of symptomatic endometriosis with norethindrone acetate. Clin J Womens Health. 2001;1:69.
   Google Scholar
• Muneyyirci-Delale O, Anopa J, Charles C, et al. Medical management of recurrent endometrioma with long-term norethindrone acetate. Int J Womens Health. 2012;4:149–154.
   PubMedGoogle Scholar
• Yamanaka K, Xu B, Suganuma I, et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture. Fertil Steril. 2012;97:477–482.
   PubMed Web of Science ®Google Scholar
• Fu L, Osuga Y, Morimoto C, et al. Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells. Fertil Steril. 2008;89(suppl):1344–1347.
   PubMed Web of Science ®Google Scholar
• Choi JY, Jo MW, Lee EY, et al. Dienogest enhances autophagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil Steril. 2015;104:655–664.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Bracco B, Mosconi P, et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril. 2016;105:734–743.e3.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Aimi P, Panazza S, et al. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril. 1999;72:505–508.
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril. 2001;75:485–488.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Viganò P, Somigliana E. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol. 2005;17:359–365.
   PubMed Web of Science ®Google Scholar
• Lockhat FB, Emembolu JE, Konje JC. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertil Steril. 2005;83:398–404.
   PubMed Web of Science ®Google Scholar
• Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20:1993–1998.
   PubMed Web of Science ®Google Scholar
• Bayoglu-Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011;95:492–496.
   PubMed Web of Science ®Google Scholar
• Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauteine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012;119:519–526.
   PubMed Web of Science ®Google Scholar
• Cho S, Jung JA, Lee Y, et al. Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence. Acta Obstet Gynecol Scand. 2014;93:38–44.
   PubMed Web of Science ®Google Scholar
• Drug.com. Implanon; [cited 20 Apr 2015]. Available from: http://www.drugs.com/pro/implanon.html
   Google Scholar
• Croxatto HB, Mäkäräinen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception. 1998;58(6 Suppl):91S–97S.
   PubMed Web of Science ®Google Scholar
• Mäkäräinen L, van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril. 1998;69:714–721.
   PubMed Web of Science ®Google Scholar
• Meckstroth KR, Darney PD. Implant contraception. Semin Reprod Med. 2001;19:339–354.
   PubMed Web of Science ®Google Scholar
• Ponpuckdee J, Taneepanichskul S. The effects of implanon in the symptomatic treatment of endometriosis. J Med Assoc Thai. 2005;88(Suppl 2):S7–10.
   PubMedGoogle Scholar
• Yisa SB, Okenwa AA, Husemeyer RP.Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Health Care. 2005;31:67–70.
   PubMed Web of Science ®Google Scholar
• Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis-a pilot study. Contraception. 2009;79:29–34.
   PubMed Web of Science ®Google Scholar
• Carr B, Giudice L, Dmowski WP, et al. Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study. J Endometriosis. 2013;5:105–115.
   Google Scholar
• Melis GB, Neri M, Corda V, et al. Overview of elagolix for the treatment of endometriosis. Expert Opin Drug Metab Toxicol. 2016;12:581–588.
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96:1175–1189.
   PubMed Web of Science ®Google Scholar
• Benagiano G, Bastianelli C, Farris M, et al. Selective progesterone receptor modulators: an update. Expert Opin Pharmacother. 2014;15:1403–1415.
   PubMed Web of Science ®Google Scholar
• Williams AR, Critchley HO, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007;22:1696–1704.
   PubMed Web of Science ®Google Scholar
• Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591–598.
   PubMed Web of Science ®Google Scholar
• The U.S. National Institutes of Health. Registry of Clinical trials; [cited 2016 Mar 15]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Guo SW, Liu M, Shen F, et al. Use of mifepristone to treat endometriosis: a review of clinical trials and trial-like studies conducted in China. Women’s Health (Lond Engl). 2011;7:51–70.
   PubMedGoogle Scholar
• Noble LS, Simpson ER, Johns A, et al. Aromatase expression in endometriosis. J Clin Endocrinol Metab. 1996;81:174–179.
   PubMed Web of Science ®Google Scholar
• Takayama K, Zeitoun K, Gunby RT, et al. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril. 1998;69:709–713.
   PubMed Web of Science ®Google Scholar
• Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril. 1999;72:961–969.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Zeitun KM, Takayama K, et al. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update. 2000;6:413–418.
   PubMed Web of Science ®Google Scholar
• Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril. 2006;85:1307–1318.
   PubMed Web of Science ®Google Scholar
• Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril. 2004;81:290–296.
   PubMed Web of Science ®Google Scholar
• Lall Seal S, Kamilya G, Mukherji J, et al. Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review. Fertil Steril. 2011;95:291.e15–e18.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Remorgida V, Venturini PL, et al. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. Eur J Obstet Gynecol Reprod Biol. 2014;174:117–122.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Foster WG. Reduction in endometrioma size with three months of aromatase inhibition and progestin add-back. BioMed Res Internat. 2015. Article ID 878517.
   Web of Science ®Google Scholar
• Maginnis G, Wilk J, Carroll R, et al. Assessment of progestin-only therapy for endometriosis in macaque. J Med Primatol. 2008;37(Suppl 1):52–55.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhu Y, Zhou X, et al. Evaluation of biodegradable microspheres containing nomegestrol acetate in a rat model of endometriosis. J Pharm Sci. 2014;56C:15–20.
   Google Scholar
• Acién P, Velasco I, Acién M, et al. Treatment of endometriosis with transvaginal ultrasound-guided drainage and recombinant interleukin-2 left in the cysts: a third clinical trial. Gynecol Obstet Invest. 2010;69:203–211.
   PubMed Web of Science ®Google Scholar
• Velasco I, Campos A, Acién P. Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin releasing hormone analogue, ultrasound-guided drainage, and intracystic recombinant interleukin-2. Fertil Steril. 2005;83:873–877.
   PubMed Web of Science ®Google Scholar
• Agostini A, De Lapparent T, Collette E, et al. In situ methotrexate injection for treatment of recurrent endometriotic cysts. Eur J Obstet Gynecol Reprod Biol. 2007;130:129–131.
   PubMed Web of Science ®Google Scholar
• Shawki HE, El Morsi M, Samir A, et al. In situ methotrexate injection after transvaginal ultrasound-guided aspiration of ovarian endometriomas: a randomized controlled trial. Middle East Fertil Soc J. 2011;16:224–231.
   Google Scholar
• Hsieh CL, Shiau CS, Lo LM. Effectiveness of ultrasound-guided aspiration and sclerotherapy with 95% ethanol for treatment of recurrent ovarian endometriomas. Fertil Steril. 2009;91:2709–2713.
   PubMed Web of Science ®Google Scholar
• Gatta G, Parlato V, Di Grezia G, et al. Ultrasound-guided aspiration and ethanol sclerotherapy for treating endometrial cysts. Radiol Med. 2010;115:1330–1339.
   PubMed Web of Science ®Google Scholar
• Wang LL, Dong XQ, Shao XH, et al. Ultrasound-guided interventional therapy for recurrent ovarian chocolate cysts. Ultrasound Med Biol. 2011;37:1596–1602.
   PubMed Web of Science ®Google Scholar
• Chang MY, Hsieh CL, Shiau CS, et al. Ultrasound-guided aspiration and ethanol sclerotherapy (EST) for treatment of cyst recurrence in patients after previous endometriosis surgery: analysis of influencing factors using a decision tree. J Minim Invasive Gynecol. 2013;20:595–603.
   PubMed Web of Science ®Google Scholar
• Atilgan R, Ozkan ZS, Kuloglu T, et al. Impact of intracystic ethanol instillation on ovarian cyst diameter and adjacent ovarian tissue. Eur J Obstet Gynecol Reprod Biol. 2014 Mar;174:133–136.
   PubMed Web of Science ®Google Scholar
• García-Tejedor A, Castellarnau M, Ponce J, et al. Ethanol sclerotherapy of ovarian endometrioma: a safe and effective minimal invasive procedure. Preliminary results. Eur J Obstet Gynecol Reprod Biol. 2015;187:25–29.
   PubMed Web of Science ®Google Scholar
• Ding D, Liu X, Duan J, et al. Platelets are an unindicted culprit in the development of endometriosis: clinical and experimental evidence. Hum Reprod. 2015;30:812–832.
   PubMed Web of Science ®Google Scholar
• Xia YF, Ye BQ, Li YD, et al. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol. 2004;173:4207–4217.
   PubMed Web of Science ®Google Scholar
• Li YD, Ye BQ, Zheng SX, et al. NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis. J Biol Chem. 2009;284:4473–4483.
   PubMed Web of Science ®Google Scholar
• Liu X, Yu S, Guo SW. A pilot Study on the use of andrographolide to treat symptomatic adenomyosis. Gynecol and Min Inv Ther. 2015;3:119–126.
   Google Scholar
• Li X, Liu X, Guo SW. Histone deacetylase inhibitors as therapeutics for endometriosis. Expert Rev Obstet Gynecol. 2014;7:451–466.
   Google Scholar
• Seet LF, Toh LZ, Finger SN, et al. Valproic acid suppresses collagen by selective regulation of Smads in conjunctival fibrosis. J Mol Med (Berl). 2016;94:321–334.
   PubMed Web of Science ®Google Scholar
• Davidson DC, Hirschman MP, Spinelli SL, et al. Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals. J Immunol. 2011;186:584–591.
   PubMed Web of Science ®Google Scholar
• Vitagliano A, Noventa M, Quaranta M, et al. Statins as targeted “Magical Pills” for the conservative treatment of endometriosis: may potential adverse effects on female fertility represent the “dark Side of the Same Coin”? A systematic review of literature. Reprod Sci. 2016;23:415–428.
   PubMed Web of Science ®Google Scholar
• Nandi A, Sinha N, Ong E, et al. Is there a role for vitamin D in human reproduction? Horm Mol Biol Clin Investig. 2016;25:15–28.
   PubMed Web of Science ®Google Scholar
• Miyashita M, Koga K, Izumi G, et al. Effects of 1,25-dihydroxy vitamin D3 on endometriosis. J Clin Endocrinol Metab. 2016;101:2371–2379.
   PubMed Web of Science ®Google Scholar
• Vercellini P, De Matteis S, Somigliana E, et al. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2013;92:8–16.
   PubMed Web of Science ®Google Scholar
• Seracchioli R, Mabrouk M, Frascà C, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Steril. 2010;93:52–56.
   PubMed Web of Science ®Google Scholar
• Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet. 2015;292:37–43.
   PubMed Web of Science ®Google Scholar
• Troncon JK, Neto OB, Nogueira AA, et al. Continuous or cyclic contraceptives for endometriosis: a question still without an answer. Arch Gynecol Obstet. 2015;292:481–482.
   PubMed Web of Science ®Google Scholar
• Muzii L, di Tucci C, Achilli C, et al. Continuous versus cyclic oral contraceptives for endometriosis: any conclusive evidence? Arch Gynecol Obstet. 2015;292:477–478.
   PubMed Web of Science ®Google Scholar
• Muzii L, Di Tucci C, Achilli C, et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016;214:203–211.
   PubMed Web of Science ®Google Scholar
• Park H-J, Koo Y, Yoon B-K, et al. postoperative long-term maintenance therapy with oral contraceptives after gonadotropin-releasing hormone analog treatment in women with ovarian endometrioma. J Minim Invasive Gynecol. 2009;16:34–39.
   PubMed Web of Science ®Google Scholar
• Shaw R, Garry R, McMillan L, et al. A prospective randomized open study comparing goserelin (Zoladex) plus surgery and surgery alone in the management of ovarian endometriomas. Gynaecol Endosc. 2001;10:151–157.
   Google Scholar
• Jee BC, Lee JY, Suh CS, et al. Impact of GnRH agonist treatment on recurrence of ovarian endometriomas after conservative laparoscopic surgery. Fertil Steril. 2009;91:40–45.
   PubMed Web of Science ®Google Scholar
• Kim NY, Ryoo U, Lee D-Y, et al. The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2011;154:85–89.
   PubMed Web of Science ®Google Scholar
• Lee D-Y, Bae D-S, Yoon B-K, et al. Post-operative cyclic oral contraceptive use after gonadotrophin-releasing hormone agonist treatment effectively prevents endometrioma recurrence. Hum Reprod. 2010;25:3050–3054.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Mao H, Xu Y, et al. Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gynecol Obstet. 2016;294:201–207.
   PubMed Web of Science ®Google Scholar
• Yang XH, Ji F, AiLi A, et al. Effects of laparoscopic ovarian endometriosis cystectomy combined with postoperative GnRH-a therapy on ovarian reserve, pregnancy, and outcome recurrence. Clin Exp Obstet Gynecol. 2014;41:272–275.
   PubMed Web of Science ®Google Scholar
• Takaesu Y, Nishi H, Kojima J, et al. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. Obstet Gynaecol Res. 2016. [Epub ahead of print, May 26]. DOI:10.1111/jog.13023
   PubMedGoogle Scholar